TY - JOUR
T1 - Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus
T2 - In vitro, in vivo, and crystallographic results
AU - Song, Yongcheng
AU - Liu, Chia I.
AU - Lin, Fu Yang
AU - Joo, Hwan No
AU - Hensler, Mary
AU - Liu, Yi Liang
AU - Jeng, Wen Yih
AU - Low, Jennifer
AU - Liu, George Y.
AU - Nizet, Victor
AU - Wang, Andrew H.J.
AU - Oldfield, Eric
PY - 2009/7/9
Y1 - 2009/7/9
N2 - The gold color of Staphylococcus aureus is derived from the carotenoid staphyloxanthin, a virulence factor for the organism. Here, we report the synthesis and activity of a broad variety of staphyloxanthin biosynthesis inhibitors that inhibit the first committed step in its biosynthesis, condensation of two farnesyl diphosphate (FPP) molecules to dehydrosqualene, catalyzed by the enzyme dehydrosqualene synthase (CrtM). The most active compounds are phosphonoacetamides that have low nanomolar Ki values for CrtM inhibition and are active in whole bacterial cells and in mice, where they inhibit S. aureus disease progression. We also report the X-ray crystallographic structure of the most active compound, N-3-(3-phenoxyphenyl) propylphosphonoacetamide (IC50 = 8 nM, in cells), bound to CrtM. The structure exhibits a complex network of hydrogen bonds between the polar headgroup and the protein, while the 3-phenoxyphenyl side chain is located in a hydrophobic pocket previously reported to bind farnesyl thiodiphosphate (FsPP), as well as biphenyl phosphonosulfonate inhibitors. Given the good enzymatic, whole cell, and in vivo pharmacologic activities, these results should help guide the further development of novel antivirulence factor-based therapies for S. aureus infections.
AB - The gold color of Staphylococcus aureus is derived from the carotenoid staphyloxanthin, a virulence factor for the organism. Here, we report the synthesis and activity of a broad variety of staphyloxanthin biosynthesis inhibitors that inhibit the first committed step in its biosynthesis, condensation of two farnesyl diphosphate (FPP) molecules to dehydrosqualene, catalyzed by the enzyme dehydrosqualene synthase (CrtM). The most active compounds are phosphonoacetamides that have low nanomolar Ki values for CrtM inhibition and are active in whole bacterial cells and in mice, where they inhibit S. aureus disease progression. We also report the X-ray crystallographic structure of the most active compound, N-3-(3-phenoxyphenyl) propylphosphonoacetamide (IC50 = 8 nM, in cells), bound to CrtM. The structure exhibits a complex network of hydrogen bonds between the polar headgroup and the protein, while the 3-phenoxyphenyl side chain is located in a hydrophobic pocket previously reported to bind farnesyl thiodiphosphate (FsPP), as well as biphenyl phosphonosulfonate inhibitors. Given the good enzymatic, whole cell, and in vivo pharmacologic activities, these results should help guide the further development of novel antivirulence factor-based therapies for S. aureus infections.
UR - http://www.scopus.com/inward/record.url?scp=67649980377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649980377&partnerID=8YFLogxK
U2 - 10.1021/jm9001764
DO - 10.1021/jm9001764
M3 - Article
C2 - 19456099
AN - SCOPUS:67649980377
SN - 0022-2623
VL - 52
SP - 3869
EP - 3880
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 13
ER -